Efficacy of terazosin for overactive bladder symptoms and sexual function in patients with overactive bladder and symptomatic benign prostatic hyperplasia: a prospective multicenter trial.
- Author:
Chin Kyung DOO
1
;
Myung Soo CHOO
;
Kyu Sung LEE
;
Moon Kee CHUNG
;
Kwang Sung PARK
;
Jae Seung PAICK
;
Tae Kon HWANG
Author Information
1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Korea. mschoo@amc.seoul.kr
- Publication Type:Original Article ; Multicenter Study
- Keywords:
Prostatic hyperplasia;
Adrenergic alpha-antagonists;
Erectile function;
Overactive bladder
- MeSH:
Adrenergic alpha-Antagonists;
Humans;
Male;
Placebo Effect;
Prospective Studies*;
Prostatic Hyperplasia*;
Surveys and Questionnaires;
Urinary Bladder, Overactive*
- From:Journal of the Korean Continence Society
2008;12(1):36-41
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: This study is to evaluate the efficacy of terazosin in the treatment of overactive bladder (OAB) symptoms and sexual dysfunction in patients with symptomatic benign prostatic hyperplasia (BPH) and OAB. METHODS: Of 200 men aged 50-80 years with symptomatic BPH, an International Prostatic Symptom Score (IPSS) > or =8 accompanied by OAB symptoms, 185 patients completed treatment with terazosin 2-5 mg once daily for 8 weeks. Patients were asked to complete a voiding diary, the International Index of Erectile Function (IIEF) questionnaire, and the IPSS at baseline, 4 and 8 weeks. RESULTS: 8-week terazosin treatment improved OAB symptoms as well as reducing IPSS (19.8 to 12.7) and IIEF (34.4 to 37.4) scores. OAB symptoms improved significantly, irrespective of symptom severity by the IPSS, but the IIEF score only increased in patients with severe symptoms. CONCLUSIONS: Additional studies are needed to further evaluate the placebo effect. However, terazosin monotherapy is effective in patients with symptomatic BPH and OAB, and may increase sexual function in patients with severely symptomatic BPH.
